Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript

Good morning, everyone. We're going to get started. So it's my pleasure to welcome you this morning. My name is Michael Metzger, I'm the CEO of Syndax. A warm welcome to everybody joining us in person today and also online. We're thrilled to give you an update on our progress as we advance innovation for patients and bring more opportunities for great therapies to patients. So we will be making forward-looking statements. Here is our disclosure. Syndax is a company on the move. We're driving innovation and long-term value for patients. And we have what a few companies our size have in terms of accomplishments. We've gotten drugs approved actually and brought them to market. So we are a fully integrated commercial organization now with a track record of success, and we're lo...